Secretin helps regulate the pH of the duodenum by (1) inhibiting the secretion of gastric acid from the parietal cells of the stomach and (2) stimulating the production of bicarbonate from the ductal cells of the pancreas. It also stimulates bile production by the liver; the bile emulsifies dietary fats in the duodenum so that pancreatic lipase can act upon them. Meanwhile, in concert with secretin's actions, the other main hormone simultaneously issued by the duodenum, cholecystokinin (CCK), is stimulating the gallbladder to contract, delivering its stored bile for the same reason.
Prosecretin is a precursor to secretin, which is present in digestion. Secretin is stored in this unusable form, and is activated by gastric acid. This indirectly results in the neutralisation of duodenal pH, thus ensuring no damage is done to the small intestine by the aforementioned acid.
Secretin was the first hormone to be identified. In 1902, William Bayliss and Ernest Starling were studying how the nervous system controls the process of digestion. It was known that the pancreas secreted digestive juices in response to the passage of food (chyme) through the pyloric sphincter into the duodenum. They discovered (by cutting all the nerves to the pancreas in their experimental animals) that this process was not, in fact, governed by the nervous system. They determined that a substance secreted by the intestinal lining stimulates the pancreas after being transported via the bloodstream. They named this intestinal secretion secretin. Secretin was the first such "chemical messenger" identified. This type of substance is now called a hormone, a term coined by Starling in 1905.
Secretin is initially synthesized as a 120 amino acid precursor protein known as prosecretin. This precursor contains an N-terminal signal peptide, spacer, secretin itself (residues 28-54), and a 72-amino acid C-terminal peptide.
Secretin is synthesized in cytoplasmic secretory granules of S-cells, which are found mainly in the mucosa of the duodenum, and in smaller numbers in the jejunum of the small intestine.
Secretin is released into circulation and/or intestinal lumen in response to low duodenal pH that ranges between 2 and 4.5 depending on species; the acidity is due to hydrochloric acid in the chyme that enters the duodenum from the stomach via the pyloric sphincter. Also, the secretion of secretin is increased by the products of protein digestion bathing the mucosa of the upper small intestine.
Secretin release is inhibited by H2 antagonists, which reduce gastric acid secretion. As a result, if the pH in the duodenum increases above 4.5, secretin cannot be released.
Secretin targets the pancreas; pancreatic centroacinar cells have secretin receptors in their plasma membrane. As secretin binds to these receptors, it stimulates adenylate cyclase activity and converts ATP to cyclic AMP. Cyclic AMP acts as second messenger in intracellular signal transduction and causes the organ to secrete a bicarbonate-rich fluid that flows into the intestine. Bicarbonate is a base that neutralizes the acid, thus establishing a pH favorable to the action of other digestive enzymes in the small intestine.
Secretin is found in the magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus and along the neurohypophysial tract to neurohypophysis. During increased osmolality, it is released from the posterior pituitary. In the hypothalamus, it activates vasopressin release. It is also needed to carry out the central effects of angiotensin II. In the absence of secretin or its receptor in the gene knockout animals, central injection of angiotensin II was unable to stimulate water intake and vasopressin release.
It has been suggested that abnormalities in such secretin release could explain the abnormalities underlying type D syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH). In these individuals, vasopressin release and response are normal, although abnormal renal expression, translocation of aquaporin 2, or both are found. It has been suggested that "Secretin as a neurosecretory hormone from the posterior pituitary, therefore, could be the long-sought vasopressin independent mechanism to solve the riddle that has puzzled clinicians and physiologists for decades."
Secretin and its receptor are found in discrete nuclei of the hypothalamus, including the paraventricular nucleus and the arcuate nucleus, which are the primary brain sites for regulating body energy homeostasis. It was found that both central and peripheral injection of Sct reduce food intake in mouse, indicating an anorectic role of the peptide. This function of the peptide is mediated by the central melanocortin system.
Secretin is used in a diagnostic tests for pancreatic function; secretin is injected and the pancreatic output can then be imaged with magnetic resonance imaging, a noninvasive procedure, or secretions generated as a result can gathered either through an endoscope or through tubes inserted through the mouth, down into the duodenum.
A recombinant human secretin has been available since 2004 for these diagnostic purposes. There were problems with the availability of this agent from 2012 to 2015.
A wave of enthusiasm for secretin as a possible treatment for autism arose in the 1990s based on a hypothetical gut-brain connection; as a result the NIH ran a series of clinical trials that showed that secretin was not effective, which brought an end to popular interest.
A high-affinity and optimized secretin receptor antagonist (Y10,c[E16,K20],I17,Cha22,R25)sec(6-27) has been designed and developed which has allowed the structural characterization of secreting inactive conformation.
^Polak JM, Coulling I, Bloom S, Pearse AG (1971). "Immunofluorescent localization of secretin and enteroglucagon in human intestinal mucosa". Scandinavian Journal of Gastroenterology. 6 (8): 739-44. doi:10.3109/00365527109179946. PMID4945081.
^ abFrohman, Lawrence A.; Felig, Philip (2001). "Gastrointestinal Hormones and Carcinoid Syndrome". In Ghosh, P. K.; O'Dorisio, T. M. (eds.). Endocrinology & metabolism. New York: McGraw-Hill, Medical Pub. Div. pp. 1675-701. ISBN978-0-07-022001-0.
^Ganong, William F. (2003). "Regulation of Gastrointestinal Function". Review of Medical Physiology (21st ed.). New York: McGraw-Hill, Medical Pub. Div. ISBN978-0-07-140236-1.[page needed]
^Rominger JM, Chey WY, Chang TM (1981). "Plasma secretin concentrations and gastric pH in healthy subjects and patients with digestive diseases". Digestive Diseases and Sciences. 26 (7): 591-7. doi:10.1007/BF01367670. PMID7249893. S2CID7039025.
^ abHall, John E.; Guyton, Arthur C. (2006). Textbook of medical physiology. St. Louis, Mo: Elsevier Saunders. pp. 800-1. ISBN978-0-7216-0240-0.
^Gardner, JD (1978). "Receptors and gastrointestinal hormones". In Sleisenger, MH; Fordtran, JS (eds.). Gastrointestinal Disease (2nd ed.). Philadelphia: WB Saunders Company. pp. 179-95.
^Palmer, KR; Penman, ID (2010). "Alimentary track and pancreatic disease". In Colledge, NR; Walker, BR; Ralston, SH (eds.). Davidson's Principles and Practice of Medicine (20th ed.). Edinburgh: Churchill Livingstone. p. 844. ISBN978-0-7020-3085-7.
^Boron, Walter F.; Boulpaep, Emile L. (2012). "Acid secretion". Medical Physiology (2nd ed.). Philadelphia: Saunders. p. 1352. ISBN978-1-4377-1753-2.
^Domínguez Muñoz, J. Enrique (June 2010). "Diagnosis of chronic pancreatitis: Functional testing". Best Practice & Research Clinical Gastroenterology. 24 (3): 233-241. doi:10.1016/j.bpg.2010.03.008. PMID20510825.
^Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW (1999). "Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder". The New England Journal of Medicine. 341 (24): 1801-6. doi:10.1056/NEJM199912093412404. PMID10588965.
Lee LT, Lam IP, Chow BK (2008). "A functional variable number of tandem repeats is located at the 5' flanking region of the human secretin gene plays a downregulatory role in expression". Journal of Molecular Neuroscience. 36 (1-3): 125-31. doi:10.1007/s12031-008-9083-5. PMID18566919. S2CID29982279.
Nussdorfer GG, Bahçelioglu M, Neri G, Malendowicz LK (2000). "Secretin, glucagon, gastric inhibitory polypeptide, parathyroid hormone, and related peptides in the regulation of the hypothalamus- pituitary-adrenal axis". Peptides. 21 (2): 309-24. doi:10.1016/S0196-9781(99)00193-X. PMID10764961. S2CID42207065.
Lossi L, Bottarelli L, Candusso ME, Leiter AB, Rindi G, Merighi A (2004). "Transient expression of secretin in serotoninergic neurons of mouse brain during development". The European Journal of Neuroscience. 20 (12): 3259-69. doi:10.1111/j.1460-9568.2004.03816.x. PMID15610158. S2CID398304.
Yamagata T, Aradhya S, Mori M, Inoue K, Momoi MY, Nelson DL (2002). "The human secretin gene: fine structure in 11p15.5 and sequence variation in patients with autism". Genomics. 80 (2): 185-94. doi:10.1006/geno.2002.6814. PMID12160732.
Onori P, Wise C, Gaudio E, Franchitto A, Francis H, Carpino G, Lee V, Lam I, Miller T, Dostal DE, Glaser SS (2010). "Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor". International Journal of Cancer. 127 (1): 43-54. doi:10.1002/ijc.25028. PMID19904746. S2CID2789418.